ISRCTN12196200已完成未知
Hand Osteoarthritis: investigating Pain Effects in a randomised placebo-controlled feasibility study of Estrogen-containing therapy (HOPE-e)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 28
研究概览
简要总结
2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34167594/ (added 28/06/2021) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36341025/ (added 08/11/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Current inclusion criteria as of 28/02/2020:
- •1. Able to give informed written consent
- •2. Female, aged 40-65 years old
- •3.1. In those with an intact uterus: At least 12 months of spontaneous amenorrhea (without any menstrual bleeding in last 12 months) and last menstrual period not more than 10 years ago
- •3.2. In those who have undergone hysterectomy or are/were using an intrauterine contraceptive device with progesterone local therapy (such as Mirena): Follicle-stimulating hormone (FSH) =30 milli-International Units per millilitre (mIU/ml) on screening blood test AND a history of menopausal symptoms in the last 1 to 10 years, in keeping with appropriate timing of menopausal status
- •4. Hand pain, aching or stiffness on most days in the last 3 months
- •5. At least two painful hand joints of any type (interphalangeal joints (IPJ) or base of thumbs)
- •6. Fulfils ACR (American College of Rheumatology) clinical diagnostic criteria for hand OA (3 or more of following):
- •6.1 Hard tissue enlargement of 2 or more of the following joints: 2nd or 3rd distal interphalangeal joints (DIPJ), 2nd or 3rd proximal interphalangeal joints (PIPJ), first carpometacarpal joints (CMCJ)
- •6.2 Hard tissue enlargement of 2 or more of the DIPJs
- •6. 3 Less than 3 swollen metacarpophalangeal joints (MCPJ)
- •6.4 Deformity of at least one of the joints listed in first point
- •OR, for those with base of thumb osteoarthritis only not fulfilling these criteria, has clinical symptoms and examination findings consistent with base of thumb osteoarthritis
- •7. Hand pain has not responded adequately to NICE core guidance for management of OA, including the use of paracetamol or non-steroidal anti-inflammatory drug (NSAID) gel, except where there is contraindication or intolerance
- •8. Average hand pain is reported as typically more than 4 out of 10 in severity, OR average hand pain in the last 7 days of 4/10 or more on a visual analogue scale
- •9. In the Investigator’s opinion, is able and willing to comply with all trial requirements
- •Previous inclusion criteria:
- •1. Able to give informed written consent
- •2. Female, aged 40-65 years old
- •3.1. In those with an intact uterus: At least 12 months of spontaneous amenorrhea (without any menstrual bleeding in last 12 months) and last menstrual period not more than 10 years ago
- •3.2. In those who have undergone hysterectomy or are using an intrauterine contraceptive device with progesterone local therapy (such as Mirena): Follicle stimulating hormone (FSH) =30 milli-International Units per millilitre (mIU/ml) on screening blood test AND a history of menopausal symptoms in the last 1 to 10 years, in keeping with appropriate timing of menopausal status (added 11/10/2019)
- •4. Hand pain, aching or stiffness on most days in the last 3 months and fulfils ACR (American College of Rheumatology) clinical diagnostic criteria for hand OA (3 or more of following):
- •4.1. Hard tissue enlargement of 2 or more of the following joints: 2nd or 3rd distal interphalangeal joints (DIPJ), 2nd or 3rd proximal interphalangeal joints (PIPJ), first carpometacarpal joints (CMCJ)
- •4.2. Hard tissue enlargement o
排除标准
- •1. Other cause of hand pain, including inflammatory arthritis, connective tissue disorder, chronic pain or alternative clinical diagnosis such as tenosynovitis or carpal tunnel syndrome
- •2. Pregnancy or breastfeeding, or risk of this during study
- •3. Use of one or more prohibited treatments within specified time frame, or not willing to avoid treatment for the duration of the study:
- •3.1. Oral contraceptive pill, or systemic HRT within the last 6 months?
- •3.2. Anti-estrogen medication within the last 6 months
- •3.3. Oral, intramuscular or intraarticular steroid within the last 3 months
- •3.4. Intraarticular hyaluronan to a hand joint within the last 6 months
- •3.5. Initiation of new oral analgesia within last 4 weeks
- •3.6. Initiation of glucosamine, chondroitin, hand exercises or other relevant non-pharmacological therapy within last 6 weeks
- •3.7. Hand surgery within the last 6 months, or planned within the next 6 months
- •3.8. Medications likely to increase hepatic metabolism of study medication, including:
- •3.8.1. St John’s Wort
- •3.8.2. Anti-convulsants (phenobarbital, phenytoin, carbamazepine, lamotrigine)
- •3.8.3. Some anti-infectives (rifampicin, rifabutin, nevirapine, efavirenz, ritonavir and nelfinavir)
- •4. Presence of one or more medical contraindications to the use of systemic hormonal replacement therapy:
- •4.1. Any history of breast, endometrial, ovarian or skin cancer
- •4.2. Any other history of other cancer within 5 years (except treated Basal Cell Carcinoma)
- •4.3. Relevant breast issue on routine national breast screening in prior 3 years
- •4.4. Undiagnosed genital bleeding, or untreated endometrial hyperplasia, active uterine fibroids or endometriosis
- •4.5. Active or past history of venous thromboembolism (VTE) (including deep venous thrombosis, pulmonary embolism and retinal vein thrombosis), or at high risk of VTE (such as known thrombophilic disorders (such as Protein C, S or anti-thrombin deficiency) or presence of a strong family history of VTE¥)
- •4.6. Active or past history of arterial thrombo-embolic disease (such as myocardial infarction, angina or stroke) or strong family history of stroke¥)
- •4.7. Clinically significant immobility
- •4.8. Migraine or active epilepsy
- •4.9. Uncontrolled hypertension (or diastolic pressure greater than 90 mmHg or systolic pressure greater than 145 mmHg at screening visit)
- •4.10. Uncontrolled diabetes mellitus or uncontrolled hypertriglyceridaemia
- •4.11. Body Mass Index greater than 30
- •4.12. Active malabsorption syndrome or clinically significant small bowel disease
- •4.13. Acute liver disease, clinically significant abnormal liver function, active gallbladder disease or porphyria
- •4.14. Clinically significant renal impairment
- •4.15. Intolerance to lactose, fructose or glucose (including galactose intolerance, lactase deficiency, fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency)
- •4.16.Known sensitivity to either conjugated equine estrogens, bazedoxifene or the combination
研究者
相似试验
招募中
不适用
Sensitization in hand OsteoArthritis paiHand Osteoarthritis10023213NL-OMON52315eids Universitair Medisch Centrum132
进行中（未招募）
不适用
Hand Osteoarthritis: Investigating Pain Trajectories and Association With Biomarkers Including Estrogen CohortHand OsteoarthritisNCT05105854University of Oxford120
已完成
3 期
Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand OsteoarthritisHand OsteoarthritisNCT02477059Assistance Publique - Hôpitaux de Paris104
招募中
不适用
Pulsed Radiofrequency Therapy for Hand OsteoArthritis PainHand OsteoarthritisNCT05217979Leiden University Medical Center60
已完成
不适用
Can we Use Estrogen-containing Therapy to Improve Pain in Women After Menopause With Hand Osteoarthritis?Hand OsteoarthritisNCT04036929University of Oxford28